Cumberland Pharmaceuticals Inc. (CPIX)

2.0000 +0.0300 (+1.52%) At close: 04:00PM EDT

Cumberland Pharmaceuticals Inc.

1600 West End Avenue
Nashville, TN 37203
United States
615 925 3875
https://www.cumberlandpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 83

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. A. J. Kazimi MBA	Founder, Chairman, Pres & CEO	872.63k	N/A	1958
Mr. John Michael Hamm	Sr. Director of Fin. & Accounting and CFO	304.91k	N/A	1957
Mr. James Lowrance Herman	Exec. VP of National Accounts & Chief Compliance Officer	320.65k	N/A	1955
Ms. Jean W. Marstiller	Sr. VP of Admin. Services & Corp. Sec.	N/A	N/A	1950
Ms. Cindy B. Patton	Sr. Director of Field Marketing	N/A	N/A	1953
Mr. Adam S. Mostafa	Managing Director	N/A	N/A	1980
Mr. Todd M. Anthony	VP of Organizational Devel.	N/A	N/A	N/A
Ms. Erin Smith Gull	Sr. Corp. Relations Associate	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.